Loading...
|
Please use this identifier to cite or link to this item:
http://ir.nhri.org.tw/handle/3990099045/14507
|
| Title: | Potential roles of gut microbiome in patients with hepatocellular carcinoma treated with immune checkpoint inhibitors |
| Authors: | Su, YY;Lee, WH;Wang, JH;Wang, HW;Chen, TW;Chen, BB;Ho, HJ;Liu, TH;Chou, SC;Chen, BR;Liu, TW;Chen, LT;Wu, CY;Hsu, C |
| Contributors: | National Institute of Cancer Research |
| Abstract: | Background: Gut microbiome may modulate the host immune system and correlate with antitumor efficacy of immune checkpoint inhibitor (ICI) therapy. This study explored whether gut microbiome may serve as a biomarker for ICI efficacy for HCC in a prospective study. Methods: Details of trial design were disclosed in ClinicalTrials.gov (NCT03510871). Patients with potentially resectable HCC received nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every 3 weeks (N+I). Enrolled subjects were evaluated for surgery after 2 to 4 cycles of N+I. Bacterial DNA was extracted from stool samples, collected before the start of the first cycle, after 2 and 4 cycles of N+I, and at the end-of-treatment, for 16S rRNA sequencing. Quality-filtered reads were used to generate operational taxonomic units. The alpha-diversity comparison was carried out by Kruskal-Wallis test. Principal coordinate analysis was performed to analyze similarities between groups. Results: From February 2019 to January 2021, 66 stool samples were collected from 28 subjects (men/women 22/6, median age 62 years, HBsAg+/ anti-HCV+ 16/3, BCLC stage A/B/C 2/8/18, median tumor size 8.6 cm (range 7.5-11.5), median alpha-fetoprotein 81 ng/mL [range 8-1352]). There were 7 (25%) partial responses, 10 (35.7%) stable diseases, and 11 (39.3%) progressive diseases, and 15 subjects received curative surgery. As of February 2021 (median follow-up 13.4 months), 13 subjects remained progression-free. The diversities of gut microbiome were similar between subjects with or without progression, while the abundance of some bacteria was significantly higher in subjects without tumor progression. Conclusion: We observed a trend that the abundance of some bacteria was significantly higher in non-progressed subjects. This study will enroll a total of 40 subjects to clarify whether gut microbiome may serve as a predictive or prognostic biomarker in HCC patients treated with ICI therapy. |
| Date: | 2022-07 |
| Relation: | Annals of Oncology. 2022 Jul;33(Suppl. 6):S484. |
| Link to: | http://dx.doi.org/10.1016/j.annonc.2022.05.110 |
| JIF/Ranking 2023: | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0923-7534&DestApp=IC2JCR |
| Cited Times(WOS): | https://www.webofscience.com/wos/woscc/full-record/WOS:000834940400210 |
| Appears in Collections: | [蘇勇曄] 會議論文/會議摘要
[陳立宗] 會議論文/會議摘要
[劉滄梧] 會議論文/會議摘要
|
Files in This Item:
| File |
Description |
Size | Format | |
|---|
| ISI000834940400210.pdf | | 96Kb | Adobe PDF | 126 | View/Open |
|
All items in NHRI are protected by copyright, with all rights reserved.
|
